THE GENERAL HOSPITAL CORPORATION - ENHANCE FDA SOURCE MODEL BY INCORPORATING AND ANALYZING STATE AND REGIONAL-LEVEL DATA BAA- FY24C3DP4
Key Details
Description
ENHANCE FDA SOURCE MODEL BY INCORPORATING AND ANALYZING STATE AND REGIONAL-LEVEL DATA BAA- FY24C3DP4
Context & Analysis
On Feb 4, 2026, Department of Health and Human Services obligated $268,666.53 to THE GENERAL HOSPITAL CORPORATION for enhance fda source model by incorporating and analyzing state and regional-level data baa- fy24c3dp4. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BOSTON, MA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.